Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Feb;15(2):194-202.
doi: 10.1093/eurjhf/hfs153. Epub 2012 Oct 11.
Robert J Mentz, Mary J Kwasny, Angela J Fought, Mark Huffman, Haris Subacius, Savina Nodari, Marvin Konstam, Karl Swedberg, Aldo P Maggioni, Faiez Zannad, Robert O Bonow, Mihai Gheorghiade; EVEREST investigators
Affiliations
- PMID: 23059198
- PMCID: PMC4176083
- DOI: 10.1093/eurjhf/hfs153
Randomized Controlled Trial
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial
Satyam Sarma et al. Eur J Heart Fail. 2013 Feb.
Abstract
Aims: We evaluated the impact of diabetes mellitus (DM) and diabetic therapy on outcomes in patients with reduced ejection fraction (EF) after hospitalization for heart failure (HF). DM is prevalent in patients hospitalized with HF, yet inconclusive data exist on the post-discharge outcomes of this patient population.
Methods and results: Post-hoc analysis was performed on the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) study, a randomized trial of patients hospitalized with HF (n = 4133) with median follow-up of 9.9 months. DM status was determined from intake questionnaires and cross-verified by medication history. Univariate relationships were examined using χ(2) test, t-test, and Wilcoxon tests. The two primary outcomes of (i) all-cause mortality (ACM) and (ii) cardiovascular mortality or HF hospitalization (CVM + HFH) were assessed for those with and without DM and by diabetic treatment strategy using log rank tests and multivariable Cox regression models. DM was present in 40% of participants. Patients with DM were more likely to have hypertension, coronary artery disease, and chronic kidney disease. Diabetes was associated with ACM and CVM + HFH (both P < 0.001). Following multivariate risk adjustment, DM was associated with ACM, but this estimate was imprecise [hazard ratio (HR) 1.16; 95% confidence interval (CI) 1.00-1.34] and remained associated with CVM or HFH (HR 1.17; 95% CI 1.04-1.31). Diabetic control strategy did not independently affect outcomes.
Conclusion: Diabetes is common in patients hospitalized for heart failure with a reduced EF. These patients have a higher post-discharge CVM and higher HF hospitalizations compared with patients with no diabetes. Different diabetic treatment regimens did not appear to influence post-discharge outcomes.
Figures
Figure 1
Cox proportional hazards model comparing rates of age-adjusted cardiovascular mortality or heart failure re-hospitalization in patients with and without diabetes.
Similar articles
- Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Ambrosy AP, et al. Am Heart J. 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29. Am Heart J. 2013. PMID: 23351825 Clinical Trial. - Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M; EVEREST Trial Investigators. Khan SS, et al. Am J Cardiol. 2015 Mar 15;115(6):790-6. doi: 10.1016/j.amjcard.2014.12.045. Epub 2015 Jan 6. Am J Cardiol. 2015. PMID: 25728846 - Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA. Shah AN, et al. Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19. Am J Cardiol. 2012. PMID: 22999071 - Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX, Liang S, Gao L, Liu H. Li CX, et al. PLoS One. 2021 Feb 19;16(2):e0244689. doi: 10.1371/journal.pone.0244689. eCollection 2021. PLoS One. 2021. PMID: 33606705 Free PMC article. - Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
Kiuchi S, Ikeda T. Kiuchi S, et al. Intern Med. 2019 Feb 15;58(4):471-475. doi: 10.2169/internalmedicine.1697-18. Epub 2018 Sep 12. Intern Med. 2019. PMID: 30210135 Free PMC article. Review.
Cited by
- Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study.
Salvador D Jr, Bano A, Wehrli F, Gonzalez-Jaramillo V, Laimer M, Hunziker L, Muka T. Salvador D Jr, et al. Cardiovasc Diabetol. 2023 Jul 12;22(1):174. doi: 10.1186/s12933-023-01903-7. Cardiovasc Diabetol. 2023. PMID: 37438747 Free PMC article. - Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice.
Desai DA, Baby A, Ananthamohan K, Green LC, Arif M, Duncan BC, Kumar M, Singh RR, Koch SE, Natesan S, Rubinstein J, Jegga AG, Sadayappan S. Desai DA, et al. J Mol Cell Cardiol Plus. 2024 Jun;8:100075. doi: 10.1016/j.jmccpl.2024.100075. Epub 2024 Apr 4. J Mol Cell Cardiol Plus. 2024. PMID: 38957358 Free PMC article. - Impact of insulin therapy on outcomes of diabetic patients with heart failure: A systematic review and meta-analysis.
Liu J, Hu X. Liu J, et al. Diab Vasc Dis Res. 2022 May-Jun;19(3):14791641221093175. doi: 10.1177/14791641221093175. Diab Vasc Dis Res. 2022. PMID: 35543342 Free PMC article. - Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus.
Alkagiet S, Tziomalos K. Alkagiet S, et al. World J Diabetes. 2020 May 15;11(5):150-154. doi: 10.4239/wjd.v11.i5.150. World J Diabetes. 2020. PMID: 32477451 Free PMC article.
References
- Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725–2736. - PubMed
- MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–1385. - PubMed
- De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, Bauters C. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25:656–662. - PubMed
- Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Am Heart J. 2007;54(277):e1–e8. - PubMed
- Fonarow GC, Adams KF, Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous